Valuation: DaShenLin Pharmaceutical Group Co., Ltd.

Capitalization 19.67B 2.79B 2.37B 2.22B 2.09B 3.84B 252B 4.2B 25.89B 10.04B 119B 10.46B 10.24B 434B P/E ratio 2025 *
16.8x
P/E ratio 2026 * 13.9x
Enterprise value 17.83B 2.53B 2.15B 2.01B 1.89B 3.48B 229B 3.81B 23.48B 9.11B 108B 9.48B 9.28B 394B EV / Sales 2025 *
0.64x
EV / Sales 2026 * 0.55x
Free-Float
33.49%
Yield 2025 *
3.49%
Yield 2026 * 3.84%
More valuation ratios * Estimated data
Dynamic Chart
10-29 DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
08-28 DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
04-25 DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
04-25 DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
15/10/24 DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024 CI
19/09/24 Tranche Update on DaShenLin Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on May 7, 2024. CI
17/09/24 DaShenLin Pharmaceutical Group Co., Ltd.'s Equity Buyback announced on May 7, 2024, has closed with 6,722,254 shares, representing 0.59% for CNY 100.72 million. CI
30/08/24 DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 CI
02/07/24 Tranche Update on DaShenLin Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on May 7, 2024. CI
06/05/24 DaShenLin Pharmaceutical Group Co., Ltd. commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on April 1, 2024. CI
28/04/24 DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
27/04/24 DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
18/03/24 Dashenlin Pharmaceutical to Buy Back Up to 200 Million Yuan Shares MT
More news
1 day+0.41%
1 week-3.14%
Current month-2.26%
1 month-11.03%
3 months-0.63%
6 months+3.41%
Current year+14.67%
More quotes
1 week 17.1
Extreme 17.1
18.03
1 month 17.1
Extreme 17.1
19.3
Current year 13.5
Extreme 13.5
19.96
1 year 13.5
Extreme 13.5
19.96
3 years 11.92
Extreme 11.92
37.08
5 years 11.92
Extreme 11.92
61.63
10 years 11
Extreme 11.0028
61.63
More quotes
Manager TitleAgeSince
Chief Executive Officer 43 27/02/2019
Director of Finance/CFO 43 09/05/2018
Human Resources Officer 47 -
Director TitleAgeSince
Chairman 58 15/07/2013
Director/Board Member 62 07/08/2016
Chairman 47 27/05/2015
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+0.41%-3.14%+4.73%-54.47% 2.79B
+3.46%-0.75%+95.58%-25.78% 24.57B
+4.31%-2.02%+41.38%-41.81% 11.07B
+1.07%+1.31%+28.28%+37.93% 7.33B
-0.01%-2.83%-15.49%+16.50% 4.65B
-0.89%-4.29%-11.36%-44.28% 3.84B
-1.30%-1.79%-18.46%-38.36% 3.41B
+3.73%+1.82%-9.33%+75.61% 2.94B
-3.18%+1.41%+19.90% - 1.91B
-0.96%-0.26%-5.20%+14.90% 1.78B
Average +0.66%-0.57%+13.00%-6.64% 6.43B
Weighted average by Cap. +2.13%-0.78%+44.33%-15.15%
See all sector performances

Financials

2025 *2026 *
Net sales 27.83B 3.95B 3.36B 3.14B 2.95B 5.44B 357B 5.94B 36.64B 14.21B 168B 14.8B 14.49B 615B 30.97B 4.39B 3.74B 3.49B 3.29B 6.05B 398B 6.61B 40.78B 15.82B 187B 16.47B 16.13B 684B
Net income 1.18B 167M 142M 133M 125M 230M 15.11B 251M 1.55B 601M 7.12B 626M 613M 25.99B 1.41B 200M 171M 159M 150M 276M 18.14B 302M 1.86B 721M 8.55B 751M 735M 31.19B
Net Debt -1.84B -260M -222M -207M -195M -359M -23.57B -392M -2.42B -938M -11.11B -976M -956M -40.54B -2.51B -356M -303M -283M -266M -491M -32.24B -536M -3.31B -1.28B -15.2B -1.34B -1.31B -55.44B
More financial data * Estimated data
Logo DaShenLin Pharmaceutical Group Co., Ltd.
DaShenLin Pharmaceutical Group Co Ltd is a China-based company principally engaged in the pharmaceutical retailing business. The Company's primary business includes direct sales and retailing of Chinese and Western medicine, ginseng nourishing herbs and Chinese medicine pieces, health products, medical apparatus and instruments and other commodities. The Company mainly conducts its business within domestic market.
Employees
43,532
More about the company
Date Price Change Volume
12/12/25 17.27 ¥ +0.41% 5,599,218
11/12/25 17.20 ¥ -1.43% 3,461,676
10/12/25 17.45 ¥ +0.06% 3,902,320
09/12/25 17.44 ¥ -0.17% 4,829,540
08/12/25 17.47 ¥ -2.02% 8,778,970

End-of-day quote Shanghai S.E., December 11, 2025

More quotes
Trader
Investor
Global
Quality
ESG MSCI
BB
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
17.27CNY
Average target price
23.71CNY
Spread / Average Target
+37.30%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. 603233 Stock